Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 360 (9326), 7-22

MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial

Clinical Trial

MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial

Heart Protection Study Collaborative Group. Lancet.

Abstract

Background: Throughout the usual LDL cholesterol range in Western populations, lower blood concentrations are associated with lower cardiovascular disease risk. In such populations, therefore, reducing LDL cholesterol may reduce the development of vascular disease, largely irrespective of initial cholesterol concentrations.

Methods: 20,536 UK adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive 40 mg simvastatin daily (average compliance: 85%) or matching placebo (average non-study statin use: 17%). Analyses are of the first occurrence of particular events, and compare all simvastatin-allocated versus all placebo-allocated participants. These "intention-to-treat" comparisons assess the effects of about two-thirds (85% minus 17%) taking a statin during the scheduled 5-year treatment period, which yielded an average difference in LDL cholesterol of 1.0 mmol/L (about two-thirds of the effect of actual use of 40 mg simvastatin daily). Primary outcomes were mortality (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity.

Findings: All-cause mortality was significantly reduced (1328 [12.9%] deaths among 10,269 allocated simvastatin versus 1507 [14.7%] among 10,267 allocated placebo; p=0.0003), due to a highly significant 18% (SE 5) proportional reduction in the coronary death rate (587 [5.7%] vs 707 [6.9%]; p=0.0005), a marginally significant reduction in other vascular deaths (194 [1.9%] vs 230 [2.2%]; p=0.07), and a non-significant reduction in non-vascular deaths (547 [5.3%] vs 570 [5.6%]; p=0.4). There were highly significant reductions of about one-quarter in the first event rate for non-fatal myocardial infarction or coronary death (898 [8.7%] vs 1212 [11.8%]; p<0.0001), for non-fatal or fatal stroke (444 [4.3%] vs 585 [5.7%]; p<0.0001), and for coronary or non-coronary revascularisation (939 [9.1%] vs 1205 [11.7%]; p<0.0001). For the first occurrence of any of these major vascular events, there was a definite 24% (SE 3; 95% CI 19-28) reduction in the event rate (2033 [19.8%] vs 2585 [25.2%] affected individuals; p<0.0001). During the first year the reduction in major vascular events was not significant, but subsequently it was highly significant during each separate year. The proportional reduction in the event rate was similar (and significant) in each subcategory of participant studied, including: those without diagnosed coronary disease who had cerebrovascular disease, or had peripheral artery disease, or had diabetes; men and, separately, women; those aged either under or over 70 years at entry; and--most notably--even those who presented with LDL cholesterol below 3.0 mmol/L (116 mg/dL), or total cholesterol below 5.0 mmol/L (193 mg/dL). The benefits of simvastatin were additional to those of other cardioprotective treatments. The annual excess risk of myopathy with this regimen was about 0.01%. There were no significant adverse effects on cancer incidence or on hospitalisation for any other non-vascular cause.

Interpretation: Adding simvastatin to existing treatments safely produces substantial additional benefits for a wide range of high-risk patients, irrespective of their initial cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rates of myocardial infarction, of stroke, and of revascularisation by about one-quarter. After making allowance for non-compliance, actual use of this regimen would probably reduce these rates by about one-third. Hence, among the many types of high-risk individual studied, 5 years of simvastatin would prevent about 70-100 people per 1000 from suffering at least one of these major vascular events (and longer treatment should produce further benefit). The size of the 5-year benefit depends chiefly on such individuals' overall risk of major vascular events, rather than on their blood lipid concentrations alone.

Comment in

  • Two decades of progress in preventing vascular disease.
    Yusuf S. Yusuf S. Lancet. 2002 Jul 6;360(9326):2-3. doi: 10.1016/S0140-6736(02)09358-3. Lancet. 2002. PMID: 12114031 No abstract available.
  • The Heart Protection Study: implications for clinical practice. The benefits of statin therapy do not come without financial cost.
    Hamilton-Craig I. Hamilton-Craig I. Med J Aust. 2002 Oct 21;177(8):407-8. Med J Aust. 2002. PMID: 12381246 No abstract available.
  • MRC/BHF Heart Protection Study.
    Vaughan CJ, Buckley BM; MRC/BHF Heart Protection Study. Vaughan CJ, et al. Lancet. 2002 Nov 30;360(9347):1780-1; author reply 1783-4. doi: 10.1016/s0140-6736(02)11686-2. Lancet. 2002. PMID: 12480446 No abstract available.
  • MRC/BHF Heart Protection Study.
    Robins SJ, Despres JP; MRC/BHF Heart Protection Study. Robins SJ, et al. Lancet. 2002 Nov 30;360(9347):1780; author reply 1783-4. doi: 10.1016/s0140-6736(02)11685-0. Lancet. 2002. PMID: 12480447 No abstract available.
  • MRC/BHF Heart Protection Study.
    Wald N, Law M; MRC/BHF Heart Protection Study. Wald N, et al. Lancet. 2002 Nov 30;360(9347):1781; author reply 1783-4. doi: 10.1016/s0140-6736(02)11687-4. Lancet. 2002. PMID: 12480448 No abstract available.
  • MRC/BHF Heart Protection Study.
    Durrington PN; MRC/BHF Heart Protection Study. Durrington PN, et al. Lancet. 2002 Nov 30;360(9347):1781; author reply 1783-4. doi: 10.1016/s0140-6736(02)11688-6. Lancet. 2002. PMID: 12480449 No abstract available.
  • MRC/BHF Heart Protection Study.
    Bates CJ; MRC/BHF Heart Protection Study. Bates CJ, et al. Lancet. 2002 Nov 30;360(9347):1781-2; author reply 1783-4. doi: 10.1016/s0140-6736(02)11689-8. Lancet. 2002. PMID: 12480450 No abstract available.
  • MRC/BHF Heart Protection Study.
    Brown MJ; MRC/BHF Heart Protection Study. Brown MJ, et al. Lancet. 2002 Nov 30;360(9347):1782; author reply 1783-4. doi: 10.1016/s0140-6736(02)11690-4. Lancet. 2002. PMID: 12480451 No abstract available.
  • MRC/BHF Heart Protection Study.
    Violi F, Micheletta F, Iuliano L; MRC/BHF Heart Protection Study. Violi F, et al. Lancet. 2002 Nov 30;360(9347):1782-3; author reply 1783-4. doi: 10.1016/s0140-6736(02)11691-6. Lancet. 2002. PMID: 12480452 No abstract available.
  • Simvastatin reduced mortality and vascular events in high-risk patients.
    Kumana CR, Cheung BM, Lauder IJ. Kumana CR, et al. ACP J Club. 2003 Jan-Feb;138(1):2-3. ACP J Club. 2003. PMID: 12511114 No abstract available.
  • Heart Protection Study.
    Metcalfe RS, Dawson S, Milne RJ. Metcalfe RS, et al. Lancet. 2003 Feb 8;361(9356):528; author reply 529-30. doi: 10.1016/S0140-6736(03)12472-5. Lancet. 2003. PMID: 12583966 No abstract available.
  • Heart Protection Study.
    Poli A, Catapano A. Poli A, et al. Lancet. 2003 Feb 8;361(9356):528; author reply 529-30. doi: 10.1016/S0140-6736(03)12473-7. Lancet. 2003. PMID: 12583967 No abstract available.
  • Heart Protection Study.
    Wilmshurst P. Wilmshurst P. Lancet. 2003 Feb 8;361(9356):528-9; author reply 529-30. doi: 10.1016/S0140-6736(03)12474-9. Lancet. 2003. PMID: 12583968 No abstract available.
  • More on PROSPER.
    Wierzbicki AS, Mikhailidis DP, Reynolds TM. Wierzbicki AS, et al. Lancet. 2003 Mar 29;361(9363):1135-6; author reply 1136. doi: 10.1016/S0140-6736(03)12879-6. Lancet. 2003. PMID: 12672344 No abstract available.
  • More on PROSPER.
    Baztán JJ, Hornillos M, Rodríguez-Mañas L. Baztán JJ, et al. Lancet. 2003 Mar 29;361(9363):1135; author reply 1136. doi: 10.1016/S0140-6736(03)12878-4. Lancet. 2003. PMID: 12672345 No abstract available.
  • Alzheimer's disease and angiogenesis.
    Tony JC. Tony JC. Lancet. 2003 Apr 12;361(9365):1300. doi: 10.1016/S0140-6736(03)13002-4. Lancet. 2003. PMID: 12699983 No abstract available.
  • Lipoproteins and cardiovascular risk.
    Rosch PJ. Rosch PJ. Lancet. 2003 Jun 7;361(9373):1988; author reply 1989. doi: 10.1016/S0140-6736(03)13564-7. Lancet. 2003. PMID: 12801766 No abstract available.
  • Selection bias introduced by the informed consent process.
    Bjarnason NH, Kampmann JP. Bjarnason NH, et al. Lancet. 2003 Jun 7;361(9373):1990. doi: 10.1016/S0140-6736(03)13568-4. Lancet. 2003. PMID: 12801770 No abstract available.

Summary for patients in

  • Heart protection study.
    Wilson PW. Wilson PW. Curr Cardiol Rep. 2002 Nov;4(6):486-7. Curr Cardiol Rep. 2002. PMID: 12379169 No abstract available.

Similar articles

See all similar articles

Cited by 1,429 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback